NasdaqGS:GDRX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$12.4b

Last Updated

2021/08/03 23:45 UTC

Data Sources

Company Financials +

Executive Summary

GoodRx Holdings, Inc., through its subsidiaries, provides information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. More Details


Snowflake Analysis

Exceptional growth potential with adequate balance sheet.


Similar Companies

Share Price & News

How has GoodRx Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: GDRX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: GDRX's weekly volatility (7%) has been stable over the past year.


Market Performance


7 Day Return

-0.2%

GDRX

1.5%

US Healthcare Services

0.9%

US Market


1 Year Return

n/a

GDRX

10.9%

US Healthcare Services

34.7%

US Market

Return vs Industry: Insufficient data to determine how GDRX performed against the US Healthcare Services industry.

Return vs Market: Insufficient data to determine how GDRX performed against the US Market.


Shareholder returns

GDRXIndustryMarket
7 Day-0.2%1.5%0.9%
30 Day-6.6%-0.3%0.2%
90 Day-13.8%7.2%4.7%
1 Yearn/a11.1%10.9%36.8%34.7%
3 Yearn/a122.1%120.3%62.5%52.4%
5 Yearn/a209.7%205.7%123.1%98.4%

Long-Term Price Volatility Vs. Market

How volatile is GoodRx Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is GoodRx Holdings undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: GDRX ($31.64) is trading below our estimate of fair value ($73.89)

Significantly Below Fair Value: GDRX is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: GDRX is unprofitable, so we can't compare its PE Ratio to the US Healthcare Services industry average.

PE vs Market: GDRX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate GDRX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: GDRX is overvalued based on its PB Ratio (16.6x) compared to the US Healthcare Services industry average (6.3x).


Future Growth

How is GoodRx Holdings forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?

50.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: GDRX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: GDRX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: GDRX's is expected to become profitable in the next 3 years.

Revenue vs Market: GDRX's revenue (28% per year) is forecast to grow faster than the US market (9.2% per year).

High Growth Revenue: GDRX's revenue (28% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: GDRX's Return on Equity is forecast to be high in 3 years time (24.1%)


Past Performance

How has GoodRx Holdings performed over the past 5 years?

-718.1%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: GDRX is currently unprofitable.

Growing Profit Margin: GDRX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if GDRX's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare GDRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GDRX is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (32.9%).


Return on Equity

High ROE: GDRX has a negative Return on Equity (-42.63%), as it is currently unprofitable.


Financial Health

How is GoodRx Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: GDRX's short term assets ($1.1B) exceed its short term liabilities ($63.0M).

Long Term Liabilities: GDRX's short term assets ($1.1B) exceed its long term liabilities ($698.9M).


Debt to Equity History and Analysis

Debt Level: GDRX's debt to equity ratio (88.9%) is considered high.

Reducing Debt: Insufficient data to determine if GDRX's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable GDRX has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: GDRX is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 27.6% per year.


Dividend

What is GoodRx Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate GDRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate GDRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if GDRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GDRX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of GDRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Doug Hirsch (50 yo)

6.58yrs

Tenure

US$267,650,186

Compensation

Mr. Douglas J. Hirsch, also known as Doug, serves as Co-Chief Executive Officer of GoodRx Holdings, Inc. since January 2015 and it’s a Director since September 2011. Mr. Hirsch is a Co-Founder of GoodRx, I...


CEO Compensation Analysis

Compensation vs Market: Doug's total compensation ($USD267.65M) is above average for companies of similar size in the US market ($USD11.16M).

Compensation vs Earnings: Doug's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: GDRX's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: GDRX's board of directors are considered experienced (5.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: GDRX only recently listed within the past 12 months.


Top Shareholders

Company Information

GoodRx Holdings, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: GoodRx Holdings, Inc.
  • Ticker: GDRX
  • Exchange: NasdaqGS
  • Founded: 2015
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: US$12.433b
  • Shares outstanding: 392.95m
  • Website: https://www.goodrx.com

Number of Employees


Location

  • GoodRx Holdings, Inc.
  • 2701 Olympic Boulevard
  • Suite 990
  • Santa Monica
  • California
  • 90404
  • United States

Listings


Biography

GoodRx Holdings, Inc., through its subsidiaries, provides information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company opera...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/08/03 23:45
End of Day Share Price2021/08/03 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.